Aclaris Therapeutics Q3 revenue beats analyst estimates
Overview
US biopharma firm's Q3 revenue declined yr/yr but beat analyst expectations
Q3 net loss widened yr/yr but was smaller than analysts expected
Company expects cash to fund operations through first half of 2029
Outlook
Aclaris expects to initiate Phase 2b trial of modzatinib in lichen planus in Q4 2026
Company reaffirms timeline for top line results from Phase 2 ADMIRATION trial of bosakitug in AD
Aclaris expects cash runway to fund operations through the first half of 2029
Result Drivers
ATI-052 DEVELOPMENT COSTS - Co said higher R&D expenses were mainly due to manufacturing and clinical costs for ATI-052 in AD and asthma
SUN PHARMA MILESTONE IMPACT - Co said revenue decline was mainly due to a sales milestone achieved under Sun Pharma license agreement in prior year
INCREASED G&A EXPENSES - Co attributed higher G&A costs to increased professional, legal, personnel and stock-based compensation expenses
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $1.48 mln | $1.30 mln (10 Analysts) |
Q3 Net Loss | Beat | $18.51 mln | $23.68 mln (11 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Aclaris Therapeutics, Inc. is $9.50, about 158.2% above its November 4 closing price of $3.68
Reuters Recommended Reads
Nov 4 - Dianthus Therapeutics Q3 net loss widens as clinical spending rises; sees MMN data in December
Nov 4 - Lyell Immunopharma Q3 net loss widens on higher R&D spending
Nov 4 - Aprea Therapeutics Q3 net loss widens on higher R&D spending
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)